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Successful use of a modified Goeckerman
regimen in the treatment of generalized
prurigo nodularis
To the Editor: Prurigo nodularis (PN) is a severe
morphologic manifestation of chronic pruritus.
Although the exact pathogenesis is unknown, it is
likely that neural sensitization to itch, inflammation,
and trauma contribute to the evolution of PN.
Four patients with recalcitrant generalized PN
were treated with an outpatient modified
Goeckerman regimen 5 days per week at the Uni-
versity of California San Francisco between June
2013 and February 2014 (Table I). All patients had
previously failed standard narrowband or broad-
band UVB therapy. The Goeckerman regimen con-
sisted of daily multiple-step broadband UVB therapy
followed by application of crude coal tar (CCT) and
topical corticosteroids under occlusion for 4 hours
each day. Patients were instructed to apply liquor
carbonis detergens and topical corticosteroids at
home following each session. Treatment was dis-
continued when satisfactory clinical response was
achieved.
Patients underwent a mean 45.5 sessions of
modified Goeckerman therapy, and a mean total
broadband UVB dose of 11.8 J was delivered to the
extremities, the body area receiving the highest UVB
exposure. In patients 1, 2, and 4, pruritus resolved
within the first 5 treatments and nodules flattened
over the following weeks (Fig 1). Patient 3 was noted
to be noncompliant with attendance and home
therapy and demonstrated a more prolonged course
of therapy. The only adverse events were mild
phototoxic reactions that were easily managed by
reduction of the broadband UVB dose.
Following completionof themodifiedGoeckerman
regimen, patients were instructed to continue 3Open access under CC BY-NC-ND license.sessions of broadband UVB phototherapy per week
with topical steroids applied to recalcitrant nodules as
needed. Patients 2 and 3 maintained clearance for 8
and 2.5 months before recurrence, respectively, while
patients 1 and 4 remain in remission 5 months and 7
months after treatment at the time of writing.
It is increasingly recognized that neural sensitiza-
tion to itch, neural proliferation, and neurogenic
inflammation are primary components initiating
and maintaining chronic pruritus. Nerve growth
factor (NGF) and calcitonin gene-related peptide
(CGRP) are central mediators implicated in these
processes.1-3 Furthermore, Th2 cell-derived IL-31
mediates pruritus through interaction with neural
IL-31RA.4 PN lesions demonstrate increased levels of
NGF, an increased number of dermal CGRP-positive
nerve fibers, and markedly increased levels of IL-31
mRNA.4-6
UVB radiation reduces levels of NGF and dermal
CGRP-positive nerve fibers.7 It also results in
immunosuppressive effects, which may in turn
reduce levels of IL-31.8 However, all of our patients
failed previous broadband or narrowband UVB
therapy.
It is possible that topical CCT, which produces
anti-inflammatory and antipruritic effects, increases
the efficacy of UVB radiation in PN as demonstrated
in psoriasis. Furthermore, occlusion enhances the
anti-inflammatory and antipruritic effects of topical
corticosteroids, and occlusion itself serves as a
temporary physical barrier interrupting the itch-
scratch cycle.
A modified Goeckerman regimen may be an
effective treatment for PN by targeting both neuro-
logic and inflammatory components of chronic itch.
Based on the efficacy in these patients, dermatolo-
gists should consider Goeckerman therapy for pa-
tients with severe pruritus resulting in PN, even if
they have failed standard phototherapy.
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Table I. Patient characteristics and courses of therapy
Patient Age Location
Baseline
pruritus
Duration
of
disease
Associated
condition(s) Previous therapy
Duration of
Goeckerman
therapy
Maximum daily
broadband
UVB dose Topical regimen
Adverse
events
Total broadband
UVB dose Outcome
Length of
remission
1 66
years
Trunk,
extremities,
and scalp
Severe 1.5 years Unknown Clobetasol
0.05% lotion,
hydroxyzine,
cetirizine,
isotretinoin,
narrowband
UVB
43 days 140 mJ to the
scalp and trunk,
260 mJ to the
extremities
2% coal tar, triamcinolone
0.1% ointment to the
trunk and extremities,
triamcinolone 0.1%
solution to the scalp
11
erythema
3260 mJ to
the scalp
and trunk,
4070 mJ to
the extremities
Resolution of
pruritus
Flattening
of nearly all
nodules with a
few recalcitrant
lesions on the
left arm
N/A
2 15
years
Trunk,
extremities,
and scalp
Severe 4 years Unknown Clobetasol 0.05%
ointment,
topical
tacrolimus,
broadband
UVB, modified
Goeckerman
regimen
40 days 150 mJ to the
scalp, 490 mJ
to the trunk,
1040 mJ to the
extremities
2%-10% coal tar,
clobetasol 0.05%
ointment to the
trunk and extremities,
triamcinolone 0.1%
lotion or liquor
carbonis detergens
20% in Nutraderm
to the scalp
11
erythema
3870 mJ to the
scalp and trunk,
13,500 mJ to
the extremities
Resolution of
pruritus
Complete
flattening
of nodules
on the trunk
with a few
recalcitrant
lesions on the
extremities
8 months
3 68
years
Trunk,
extremities,
and scalp
Severe 21 years Atopic
dermatitis,
hepatitis B
Clobetasol 0.05%
ointment,
hydroxyzine,
broadband
UVB, modified
Goeckerman
regimen
70 days 190 mJ to the
scalp, 310 mJ
to the trunk,
825 mJ to the
extremities
2%-5% coal tar, clobetasol
0.05% ointment to
the trunk and
extremities transitioned
to triamcinolone 0.1%
ointment, clobetasol
0.05% solution to
the scalp transitioned
to liquor carbonis
detergens 20% in
Nutraderm
11
erythema
1230 mJ to the
scalp, 20,145
mJ to the
trunk, 26,260
mJ to the
extremities
Reduction of
pruritus
Flattening of
nearly all
nodules with
a few refractory
lesions on the
extremities
2.5 months
4 60
years
Trunk,
extremities,
and scalp
Severe 301 years Unknown Clobetasol 0.05%
ointment,
narrowband
UVB
29 days 105 mJ to the
scalp, trunk,
and extremities
2% coal tar, clobetasol
0.05% ointment to the
trunk and extremities,
clobetasol 0.05%
solution to the scalp
11
erythema
3480 mJ to the
scalp, trunk,
and extremities
Resolution of
pruritus
Flattening of
the majority
of nodules
N/A
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Fig 1. Generalized prurigo nodularis. Patient 1 before (A) and after (B) a course of modified
Goeckerman therapy.
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http://dx.doi.org/10.1016/j.jaad.2014.09.050PsAPASH: A new syndrome associated with
hidradenitis suppurativa with response to
tumor necrosis factor inhibition
To the Editor: A 50-year-old man with refractory and
multitherapy-resistant hidradenitis suppurativa was
referred for evaluation after having been unsuccess-
fully treated with dapsone, oral isotretinoin, and
several cycles of antibiotics (clindamycin-rifampin,
tetracycline, cephalosporin) (Fig 1, A). He had
hidradenitis suppurativa since the age of 43 years,
wasoverweight andaheavy tobacco smoker, andhad
a medical history of acne, diabetes mellitus type 2,
arterial hypertension, hypertriglyceridemia, hiatal
hernia, depression, and psoriatic arthritis (PsA).
Active acne pustules and comedonal lesions were
observed on the face and neck; painful sterile
abscesses and hypertrophic scars were present at
the axillae and were classified as hidradenitis suppu-
rativa Hurley II stage of severity. The patient had also
erythematous scaly lesions on the scalp associated
with severe joint and diffuse inflammation leading to
the clinical diagnosis of PsA (Psoriasis Area Severity
Index score 1.2; DAS28-CRP4 5.78; pain visual analog
scale score 70). Two ulcerative lesions on his right leg
had a dusky erythematous undermined edge (Fig 1,
B), andwere clinically andhistologically diagnosed as
pyoderma gangrenosum after the exclusion of di-
agnoses including neutrophilic disorders, vasculopa-
thies, and infections. His quality of life was severely
hampered by disability and social discomfort.
Adalimumab is a highly specific tumor necrosis
factor (TNF)-alfa inhibitor, binding to both soluble
